Fax: (503) 494-6197
The hazards of intermediate endpoints†
Article first published online: 11 SEP 2007
Copyright © 2007 American Cancer Society
Volume 110, Issue 9, pages 1877–1879, 1 November 2007
How to Cite
Beer, T. M. and Ryan, C. W. (2007), The hazards of intermediate endpoints. Cancer, 110: 1877–1879. doi: 10.1002/cncr.22995
See referenced original article on pages 000–000, this issue.
- Issue published online: 18 OCT 2007
- Article first published online: 11 SEP 2007
- Manuscript Accepted: 24 JUN 2007
- Manuscript Received: 21 JUN 2007
Progression-free survival in men with advanced prostate cancer is a composite endpoint that has been neither standardized nor validated as a measure of clinical benefit in advanced prostate cancer. The absence of a progression-free survival benefit in this randomized trial of atrasentan leaves the authors uncertain with regard to the potential value of this agent in prostate cancer.